The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials.

Although the risk of abdominal pain was higher in nintedanib than placebo, the difference did not reach statistical significance (10.5% vs 4.9%; OR = 2.19; 95% CI = 1.00–4.77; P = 0.05), Whereas, patients treated with nintedanib were less likely to have a cough (12.1% vs 15.6%; OR = 0.73; 95% CI = 0.56–0.96; P = 0.02), and dyspnea (8.9% vs 12.5%; OR = 0.70; 95% CI = 0.53–0.94; P = 0.02) ( Fig 3 and S1 Fig ).

also in 111,027 other papers